EASD 2020: GLP1 Receptor Agonists Lead to Reduced Cerebral and CV Events
Fewer cerebral and cardiovascular events were reported among patients receiving this drug class.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.